Head-to-head evidence
Mayzent vs ozanimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline
Mayzent
Marketed by Novartis
NCT03623243 · Phase 3 · completed
The study was an open-label, single-arm trial with 185 participants and no placebo or active comparator, so its findings are descriptive rather than a controlled comparison. Its primary clinical endpoint was the number of participants with treatment-emergent adverse events related to siponimod; 59 participants were reported with such an event, but no comparative significance test was applicable.
ozanimod · Zeposia
Marketed by Bristol-Myers Squibb
NCT01628393 · Phase 2/3 · completed
The trial was randomized, placebo-controlled and fully blinded in 258 participants, and both ozanimod doses significantly reduced new brain lesions on MRI versus placebo. Because the primary measure was an imaging biomarker rather than a clinical outcome such as relapse rate or disability, this trial supports but does not on its own confirm a clinical benefit.
Next expected readout: August 2028 · NCT06529406 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mayzent's landscape · ozanimod's landscape